Skip to main content
. 2022 Nov 2;13:986893. doi: 10.3389/fimmu.2022.986893

Table 3.

Reproductive outcomes of IVF cycles in aPL positive women before and after hydroxychloroquine and antiplatelets treatment.

IVF laboratory outcomes Agonist protocol Antagonist protocol PPOS protocol
Before treatment (n=23) After treatment (n=21) p-value Before treatment (n=8) After treatment (n=8) p-value Before treatment (n=13) After treatment (n=12) p-value
Days of ovarian stimulation 11.8 ± 2.0 11.4 ± 2.3 0.649 9.0 ± 2.6 10.0 ± 1.2 0.454 10.1 ± 3.1 9.8 ± 2.6 0.776
Total Gn dose (IU) 2310.0 ± 1103.5 2525.0 ± 1297.0 0.681 1875.0 ± 826.7 1743.8 ± 824.7 0.818 2127.0 ± 889.1 2131.3 ± 646.3 0.804
Retrieved oocytes 12.1 ± 6.3 13.1 ± 6.1 0.662 8.6 ± 3.7 11.3 ± 7.9 0.433 5.0 ± 3.5 6.7 ± 4.6 0.341
M II oocytes rate (%) 67.1 ± 24.0 74.8 ± 17.6 0.236 64.5 ± 26.1 83.2 ± 34.1 0.271 74.3 ± 18.0 85.1 ± 14.8 0.112
Normal fertilization rate (%) 56.0 ± 27.1 72.1 ± 15.1 0.026 54.1 ± 25.5 64.1 ± 19.5 0.462 63.8 ± 25.1 75.1 ± 20.5 0.229
Embryos 7.8 ± 4.1 8.8 ± 3.0 0.525 5.4 ± 3.5 7.6 ± 4.4 0.335 3.1 ± 1.9 5.5 ± 3.7 0.062
Perfect embryos 2.5 ± 1.8 5.4 ± 1.8 0.000 1.9 ± 1.2 5.1 ± 3.1 0.022 1.7 ± 2.6 3.2 ± 2.6 0.143
Available embryos 4.1 ± 3.0 6.8 ± 3.1 0.034 2.6 ± 1.7 6.3 ± 3.0 0.015 2.6 ± 4.5 4.4 ± 4.0 0.300
Blastocyst formation rate (%) 22.5 ± 22.7 41.0 ± 14.7 0.004 20.2 ± 14.5 36.4 ± 14.7 0.125 16.3 ± 17.4 22.5 ± 20.5 0.426
Perfect embryo rate (%) 38.1 ± 23.2 65.6 ± 13.8 0.003 47.3 ± 38.3 77.3 ± 23.3 0.102 21.7 ± 24.2 61.8 ± 31.1 0.002
Available embryo rate (%) 53.2 ± 31.3 80.0 ± 16.0 0.000 60.0 ± 37.1 98.8. ± 18.1 0.035 36.3 ± 37.8 77.8 ± 29.2 0.005

aPL, antiphospholipid antibody, such as anti-cardiolipin antibody and/or β2-glycoprotein-I antibody. P-value <0.05 was considered to be statistically significant.